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Abstract
Background: Gleason scores (GS) 3 + 3 and 3 + 4 prostate cancers (PCa) differ greatly in their clinical courses, with
Gleason pattern (GP) 4 representing a major independent risk factor for cancer progression. However, Gleason grade is
not reliably ascertained by diagnostic biopsy, largely due to sampling inadequacies, subjectivity in the Gleason grading
procedure, and a lack of more objective biomarker assays to stratify prostate cancer aggressiveness. In most aggressive
cancer types, the tumor microenvironment exhibits a reciprocal pro-tumorigenic metabolic phenotype consistent
with the reverse Warburg effect (RWE). The RWE can be viewed as a physiologic response to the epithelial phenotype
that is independent of both the epithelial genotype and of direct tumor sampling. We hypothesize that differential
expression of RWE-associated genes can be used to classify Gleason pattern, distinguishing GP3 from GP4 PCa foci.
Methods: Gene expression profiling was conducted on RNA extracted from laser-capture microdissected stromal
tissue surrounding 20 GP3 and 21 GP4 cancer foci from PCa patients with GS 3 + 3 and GS ≥ 4 + 3, respectively.
Genes were probed using a 102-gene NanoString probe set targeted towards biological processes associated with
the RWE. Differentially expressed genes were identified from normalized data by univariate analysis. A top-scoring pair
(TSP) analysis was completed on raw gene expression values. Genes were analyzed for enriched Gene Ontology (GO)
biological processes and protein-protein interactions using STRING and GeneMANIA.
Results: Univariate analysis identified nine genes (FOXO1 (AUC: 0.884), GPD2, SPARC, HK2, COL1A2, ALDOA,MCT4, NRF2,
and ATG5) that were differentially expressed between GP3 and GP4 stroma (p < 0.05). However, following correction
for false discovery, only FOXO1 retained statistical significance at q < 0.05. The TSP analysis identified a significant gene
pair, namely ATG5/GLUT1. Greater expression of ATG5 relative to GLUT1 correctly classified 77.4 % of GP3/GP4 samples.
Enrichment for GO-biological processes revealed that catabolic glucose processes and oxidative stress response
pathways were strongly associated with GP3 foci but not GP4. FOXO1 was identified as being a primary nodal protein.
Conclusions: We report that RWE-associated genes can be used to distinguish between GP3 and GP4 prostate
cancers. Moreover, we find that the RWE response is downregulated in the stroma surrounding GP4, possibly via
modulation of FOXO1.
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Background
In order to assess the risk of metastasis in prostate cancer
(PCa), Gleason grading integrates the relative abundance
of cancer cells that make low-grade patterns (Gleason
pattern 3 or GP3) with those that make high-grade pat-
terns (Gleason patterns 4 or 5 or GP4 and GP5). Cancers
with more abundant high-grade patterns obtain higher
Gleason scores (GS) and have higher risk of metasta-
sis and death. Those with only low-grade cancer cells
have almost no risk of PCa-specific death [1, 2]. GS
exhibits a strong correlation with clinical outcome. How-
ever, scores are often misreported due to differences in
grading performed by individual pathologists, and under-
sampling during biopsy, which occurs in up to 30 %
of cases [3]. Prognostic biomarkers are urgently needed
to augment clinicopathologic parameters, such as GS,
in the risk stratification of this disease. Unlike other
epithelial tumors, such as breast tumors, PCa lacks con-
firmedmolecular subtypes that differ in their prognosis or
treatment response. Several biomarkers/panels that have
been identified to date have thus far not been widely
embraced by clinicians [4–11]. Notably, the gene features
among these panels exhibit little overlap, reinforcing the
notion of molecular heterogeneity in the progression of
PCa [12–15].
Emerging evidence indicates that in many cancers, the
tumor microenvironment plays a crucial role in their
phenotypic progression [16–19]. Data from cell lines
and animal models indicate that reciprocal interactions
between cancer cells and cancer-associated fibroblasts
(CAFs) facilitate growth and dissemination of tumor cells
[20–24]. Central to this reciprocal relationship is the
paradigm of altered glucose metabolism and metabolic
coupling between cancer cells and CAFs known as the
reverse Warburg effect (RWE) [25]. Specifically, cancer
cells induce oxidative stress in adjacent stroma by promot-
ing autophagy and lysosomal destruction of themitochon-
dria in CAFs, thereby diverting their favored metabolic
pathway to aerobic glycolysis. The resulting high-energy
by-products, such as lactate and ketones, are shuttled back
to the tumor cells, in which they fuel increased oxidative
phosphorylation and efficient ATP production needed for
anabolic growth [26]. Oxidative stress also enhances the
production of free radicals, resulting in increased DNA
damage and random mutagenesis in cancer cells [27, 28].
This relationship is maintained in most aggressive cancers
and is indeed recognized as one of its emerging hallmarks.
Given that the changes experienced by the stroma are
likely to be reflective of cancer growth and progression,
probing the metabolic state of CAFs may provide a means
of indirectly assessing the phenotypic state of the cancer
cells, while bypassing the problem of epithelial geno-
typic heterogeneity and the need for direct sampling of
the cancer cells themselves [29, 30]. Additionally, because
the tumor microenvironment is comprised of relatively
benign cells, its genomic features are likely to be more
reliable [31–34], making it an ideal medium in which
to profile physiological responses, such as the RWE, to
genetically dissimilar patterns of PCa.
Therefore, in this study, we compare the RWE status in
the stromal component between aggressive and indolent
PCa foci. Specifically, we compare the expression levels of
102 RWE-associated genes in the stroma adjacent to GP3
foci from GS 3 + 3 tumors to those of GP4 foci from GS
≥ 4 + 3 tumors. We report two potential classifiers that
discriminate GP3 fromGP4 tumor foci. Based on the clin-
ical behavior and the histologic features of GS 3 + 3 and
GS > 4 + 3 tumors, we propose potential roles for these
genes in establishing their respective phenotypes.
Methods
Human prostate tumor samples
This study was conducted under the approval of the
Research Ethics Board at Queen’s University. The pathol-
ogy database at the Kingston General Hospital was
queried for radical prostatectomies between the years
2001 and 2013. Through the review of the pathology
reports, suitable cases were identified for the two groups
in our cohort. The first consisted of cases of organ-
confined diseases of GS 3 + 3, with no evidence of higher
tertiary pattern. The second group consisted of diseases
with GS ≥ 4 + 3, with or without evidence of extrapro-
static involvement (Additional file 1: Table S1). Together,
the GS 3 + 3 and the GS ≥ 4 + 3 groups represent diver-
gent prognoses, “low-risk” and “intermediate to high-risk,”
respectively, for localized PCa [35]. Each of the selected
cases were retrieved for histologic review by one of two
urologic pathologists (DMB, CD) to confirm the diagno-
sis, according to the International Society of Urological
Pathology (2005) Consensus guidelines [36]. In total, 20
GS 3+3 samples and 21 GS≥ 4+3 samples were selected
for this study.
Sample processing
GP3 foci and GP4 foci were identified from hemotoxylin
and eosin-stained slides of GS 3 + 3 and GS > 4 + 3
samples, respectively. Corresponding archival formalin-
fixed paraffin-embedded (FFPE) blocks were sectioned
and mounted on slides. Stromal tissue adjacent to can-
cer foci was harvested by laser capture microdissection,
using a Zeiss PALM CombiSystem microscope. A min-
imum of 3×106 μm2 of stroma was harvested for each
sample, using multiple serial sections, where necessary, to
restrict the field of harvest to within ten cell widths from
the margin of the epithelial foci.
RNA was extracted from microdissected tissue using
the RNeasy© FFPE Kit (Qiagen, Valencia, CA, USA).
The manufacturer’s protocol was modified to substitute
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the proteinase digestion with that of Roche’s PCR-
grade recombinant Proteinase K (Roche Diagnostics
Mannheim, Germany) at 56 °C for 30min (18.6mg/ml).
The final elution step was conducted using RNase-free
water heated to 37 °C and repeated twice in order to
increase yield. RNA was quantified using the Agilent
RNA 6000 Pico Kit (Agilent Technologies, Santa Clara,
CA, USA), following manufacturer’s protocol, and stored
at −80 ◦C until use. RNA quality was assessed by smear
analysis and RNA integrity numbers (RIN) using the
Agilent 2100 Bioanalyzer.
Compilation of candidate RWE gene panel
A gene panel representative of the RWE was gen-
erated using a three-pronged in silico approach. As
a starting point, the literature was mined to identify
genes with known associations to the RWE in both
breast and prostate carcinomas [25, 27, 28, 37–42].
By design, genes from the primary list were grouped
based on primary biological function into the fol-
lowing categories: hypoxia response/oxidative stress
regulation, mitophagy, autophagy and mitochondrial dys-
function, glucose metabolism, myo-fibroblast differen-
tiation and CAF markers, and metabolite transporters.
These small groups of genes were then input into
a network-building algorithm, STRING (http://string-
db.org), and nodal points that possessed a combined
functional-evidence confidence score of greater than
0.9, with more than three of the input genes, were
noted.
Lastly, in order to further enrich the target gene list,
the following Gene Omnibus (http://geneontology.org)
[43] databases comparing the transcriptomes of laser-
captured microdissected or cultured stromal tissue
derived from normal and invasive human breast and
prostate carcinomas were accessed: GSE34312 [44],
GSE26910 [45], and GSE11682 [46]. For each dataset,
samples were assigned to either “normal-associated” or
“tumor-associated” groups based on experimental label-
ing and compared using the GEO2R analysis software
provided by the Gene Omnibus database (http://www.
ncbi.nlm.nih.gov/geo/geo2r/). GEO2R generates a list of
the top 250 differentially expressed genes, ranked by
p value. Genes with an adjusted p < 0.05, an absolute
value of the log base two fold change >1.5, and a biolog-
ical function that fits into either of the above-mentioned
categories were marked for inclusion. Genes identified
through network building and Gene Omnibus database
searches were subject to literature review prior to inclu-
sion in the final gene panel. The final panel consisted
of 102 target genes (Additional file 2: Table S2) associ-
ated with RWE for use in gene expression profiling. Five
housekeeping genes were selected for inclusion, namely
ACTB, CLTC, GUSB, HPRT1, and TUBB, as these genes
had proven suitable for normalization in previous PCa
gene expression profiling studies [47].
cDNA conversion andmultiplexed target enrichment for
nCounter analysis
Prior to hybridization, target enrichment was performed
using a multiplexed target enrichment (MTE) protocol
(NanoString Technologies, Seattle, WA, USA). Primer
pairs were designed for each of the 102 target genes
using Primer3 software. These primer pairs (Integrated
DNA Technologies, Coralville, IA, USA) flanked the
100-nucleotide target regions specific to the NanoString
probes (Additional file 3: Table S3). Two nanograms of
RNA for each sample was reverse transcribed and ampli-
fied for 20 cycles, using SuperScript VILO MasterMix
(Life Technologies, Carlsbad, CA, USA) and TaqMan©
PreAmp Master Mixes (Applied Biosystems, Foster City,
CA, USA), respectively.
Sample hybridization and nCounter analysis
A digital multiplexed NanoString nCounter analysis
(NanoString Technologies, Seattle, WA, USA) for gene
expression was performed using 11μL of denatured
amplified stromal cDNA. Each sample was probed against
the custom RWE NanoString panel, which included 102
RWE-associated genes, 5 housekeeping genes, 6 spiked-
in positive controls ranging in concentration from 128
to 0.128 fM, and 8 synthetic negative control sequences
(Additional file 4: Table S4). The hybridization reac-
tion was prepared according to the nCounter Single Cell
Expression Assay protocol (NanoString Technologies,
Seattle, WA, USA). The digital analyzer pre-processed
barcode images internally according to standard specifi-
cations for binding density and field of view (FOV). All
samples were used, as their binding density was inside the
recommended 0.05–2.25-range, and their percent FOV
was greater than 75/280.
Processing and data normalization
A protocol for NanoString gene expression data normal-
ization was developed in-house based on the NanoString-
Norm Bioconductor package [48]. Data normalization
included positive control normalization, background cor-
rection, and sample content normalization Additional
file 5: Figure S1 and Additional file 6: Figure S2. Our
housekeeping collection was not used in normaliza-
tion since only one gene, ACTB, showed reproducibility
across all samples Additional file 7: Figure S3. (Within
the NanoStringNorm package, the relevant options were
CodeCount= “geo.mean,” Background= “mean,” Sample-
Content = “top.geo.mean.”)
Briefly, the geometric mean of the six spiked-in pos-
itive controls taken across all lanes was divided by the
geometric mean of each lane to create positive control
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correction factors for each sample. Positive normalization
factors were accepted if they fell within the recommended
range of 0.3–3. Following positive control normalization,
the mean of the negative control counts was used to esti-
mate the background for each lane. This less conservative
approach allowed for low expression profile distributions
to be statistically probed. The sum of the geometric means
for the top 75 genes with the highest intensities was
divided by the sum of the top 75 genes within a single sam-
ple in order to produce a sample content normalization
factor for each lane. The sample content correction fac-
tors were then multiplied against the control-normalized
data. Sample content normalization factors were deemed
acceptable if they ranged between the standard 0.1 and 10.
Prior to our final statistical analysis, those samples with
>50% missing data were excluded. Similarly, genes with
>50% missing data across samples were discarded.
Statistical analysis
Univariate gene expression differences were assessed
using the rank-based non-parametric Mann-Whitney
U (MWU) test, appropriate for manifestly non-normal
distributions, as well as the Welch t test, noting the
nonequivalence of sample variances. To account for small
sample numbers, we employed both tests with a cutoff
of p = 0.05, being more confident in identifying expres-
sion profile differences if both the medians and means
were found to be different. The Benjamini-Hochberg false
discovery rate (FDR) correction [49], using the p.adjust
routine from R, was applied to both p values to account
for multiple comparisons, thereby producing a q value for
each test. Receiver operator curves (ROC) were generated
for genes of interest in order to determine their accuracy
in distinguishing GP3 from GP4.
Top-scoring pair (TSP) analysis [50] was used to iden-
tify pairs of genes that successfully classify GP3 fromGP4.
This method is employed to find a classifier that is not
dependent on certain subjective decisions, specifically the
calculation of sample content normalizations, or the set-
ting of arbitrary cutoffs for normalization factors made
when processing and normalizing the data, or the expres-
sion of reference genes. Here, prior to TSP analysis, raw
data were mean-background corrected, followed by the
exclusion of genes and then samples possessing >50%
zero values. Permutation testing was used to query the sig-
nificance of the top-scoring pair under the null hypothesis
that gene count is not associated with Gleason pat-
tern. One hundred thousand random classification assign-
ments were run to generate a score distribution.
Pathway analysis
Pathway analysis was conducted using STRING (http://
string-db.org) [51] and GeneMANIA (http://www.
genemania.org) [52]. All genes that exhibited an area
under the curve (AUC) greater than 0.7 in the ROC
analysis were used as input. The gene list was then aug-
mented with those having a p < 0.1 for either test with a
minimum fold change of 1. In total, 17 upregulated genes
and 4 downregulated genes, in GP3 relative to GP4, were
used as inputs. Input genes were enriched for 5 and 10
related genes in STRING. Network significance, in all
cases, was based on a GO [53] biological process-based
weighting (http://geneontology.org) with correction for
FDR. The STRING results were compared to those found
using GeneMANIA software.
Results
Assessing stromal FFPE sample quality
All RNA samples had RINs ranging between 2 and 2.5,
typical of fragmented RNA extracted from FFPE tissue
[54]. Smear analysis revealed variability in the amount of
fragmentation between samples, with the percentage of
50–300 residue length fragments ranging between 50 and
84%. Low yields and fragmentation of RNA necessitated
RNA amplification prior to profiling.
Processing and normalization of NanoString gene
expression data
All 41 samples passed binding density and FOV quality
control measures implemented by NanoString. One
sample (GP4-18) was removed during QC assessment
due to its large normalization factor. Even with the
application of the modestly conservative background
correction, low counts resulted in a significant proportion
of zero values within samples, as well as across samples
for select genes. To eliminate unreliable data, seven sam-
ples which failed to register counts in >50% of the genes
(GP3-5, GP3-6, GP3-7, GP3-12, GP3-13, GP3-20, and
GP4-12) were excluded from further analysis. Similarly,
two genes (NOS2 and TKTL1) which failed to register
counts in >50% of the samples were also excluded
from further analysis. Following data normalization and
exclusion based on missing values, 98 genes and 33 PCa
samples (15 GP3, 18 GP4) passed all thresholds set for
normalization and background correction and were
included in downstream univariate analysis.
Univariate analysis of differentially expressed genes
associated with RWE
Univariate statistical analysis was applied to normalized
gene expression data, followed by in-house data process-
ing techniques. In the present cohort, nine genes were
differentially expressed between GP3 and GP4 stroma
using both the MWU and Welch t tests (p = 0.05). These
genes (Table 1), listed in order of statistical significance,
are FOXO1, GPD2, SPARC, HK2, COL1A2, ALDOA,
SLC16A4 (MCT4), NRF2, and ATG5. Two additional
genes, SIRT3 and ACTA2, were found to be significant by
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Table 1 Differential expression of RWE-associated genes in GP3
versus GP4 stroma
Gene p (Welch t) p (MWU) q ROC (AUC) Log2 (GP4/GP3)
FOXO1 0.0008 0.0005 0.0495 0.884 –4.590
GPD2 0.0046 0.0034 – 0.707 –3.58
SPARC 0.0194 0.0119 – 0.769 3.12
HK2 0.0172 0.0132 – 0.752 –3.82
COL1A2 0.0191 0.0200 – 0.742 2.16
ALDOA 0.0118 0.0231 – 0.778 –2.60
SLC16A4 0.0392 0.0327 – 0.750 –3.43
NRF2 0.0197 0.0349 – 0.729 2.46
ATG5 0.0239 0.0410 – 0.748 –2.79
ACTA2 0.0255 0.1083 – – 0.90
SIRT3 0.0375 0.1505 – – –3.25
the Welch t test but not by the MWU test. Seven of dif-
ferentially expressed genes, FOXO1 GPD2, HK2, ALDOA,
SLC16A4, ATG5, and SIRT3, were upregulated in the
stroma from GP3 relative to GP4, while SPARC, COL1A2,
NRF2, and ACTA2 were downregulated in GP3 stroma
relative to GP4. Notably, FOXO1, SPARC, HK2, andMCT4
exhibited the highest magnitude of log2 fold changes of
4.58, 3.12, 3.81, and 3.46, respectively.
To account for multiple comparisons, a Benjamini-
Hochberg FDR correction was applied to the MWU test
values using p.adjust from the Bioconductor R package.
As expected, the FDR was very high given the small
sample size compared to the number of variables. After
correction for FDR, only one gene, FOXO1, retained sta-
tistical significance with an adjusted p value of q = 0.0495.
A notched box-and-whisker plot for this gene’s expression
values is shown in Fig. 1.
To assess the suitability of the differentially expressed
genes as classifiers, ROC curves were generated. FOXO1
produced an AUC of 0.884 (Fig. 2), suggesting a high dis-
criminatory power between GP3 and GP4. The remaining
eight genes had individual AUCs ranging between 0.71
and 0.78. Notched box-and-whisker plots for these eight
genes are shown in Fig. 3.
Pathway analysis
To establish signalling networks that may play significant
biological roles in GP3 and GP4, subject to the provision
that genes are taken only from our original RWE gene list,
STRING pathway analysis software was employed using
enrichment for the most meaningful GO biological pro-
cesses. Irrespective of the use of all 21 genes, namely 17
upregulated genes (FOXO1, GPD2, HK2, MYC, ALDOA,
MCT4, ATG5, TGFB2, TGFB3, EGLN1, GAPDH, CA9,
P4HA1, MXI1, MMP9, and PGM1) and 4 downregulated
genes (COL1A2, SPARC, NRF2, and TGFBR2) or only
those 17 genes that are upregulated in GP3 relative to GP4,
Fig. 1 Boxplot of GP3 vs. GP4 expression for FOXO1. A notched
box-and-whisker plot representing the distributions in FOXO1 gene
expression between GP3 and GP4. (The solid lines represent the
medians, and the notches show the 95% confidence intervals for the
medians. The whiskers represent 1.5 times the inter-quartile ranges.)
The y-axis represents log2 expression intensities. The upper GP3
quartile and lower GP4 quartile show minimal overlap, and the
median show significant separation, consistent with the results of the
MWU test. FOXO1 retained statistical significance even after FDR was
applied to the MWU test (q = 0.0495)
three pathways were consistently identified: “gluconeoge-
nesis,” “hexose catabolic process,” and “monosaccharide
catabolic process” (Table 2). Analysis of the protein-
protein interactions within the 26-gene network identifies
FOXO1 and AKT1 as being primary nodal points based
on their number of connecting proteins (Fig. 4). AKT1
and FOXO1 appear to directly affect one another through
reciprocal activation or inhibition in a manner that is
dependent on the overall metabolic context. Two pro-
cesses that are not found when one uses only our input
genes, but that are consistently reported upon enrichment
of five or ten related genes, are the “response to oxy-
gen levels” (p = 2.97 × 10−4) and “response to hypoxia”
(p = 3.91× 10−4). To validate these results, the same pro-
cess was repeated in GeneMANIA with the addition of
ten related gene partners. The prevalence of the glucose
catabolic pathway was recurrent in both analyses, further
substantiating this observation.
TSP analysis
In order to limit normalization biases resulting from
the small number of samples, rank-based TSP of pre-
processed raw data was also tested. However, the broad
Georgescu et al. Cancer &Metabolism  (2016) 4:8 Page 6 of 12
Fig. 2 ROC curve for FOXO1. AUC= 0.884
distribution of negative controls (Additional file 6:
Figure S2) indicated that the low intensity readings in
our raw dataset were unlikely to be reliable in its present
form. Therefore, we chose to apply background correc-
tion using the built-in exogenous negative controls. Back-
grounds were subtracted from the raw data using the
modestly conservative “mean” option in the NanoString-
Norm package.
Following mean background correction, and exclusion
of genes and samples with >50% missing data, four genes
and nine samples were excluded. Excluded genes and
excluded samples were as follows: HGMCL, IGF2, IL10,
NOS2, and TKTL1 and GP3-5, GP3-6, GP3-7, GP3-10,
GP3-12, GP3-13, GP3-14, GP3-20, and GP4-12, respec-
tively. Additionally, the single sample (GP4-18) that did
not previously pass sample content normalization due to
its large scaling factor was also removed, in order for our
treatment of the data to remain consistent between the
univariate and TSP analyses. The final dataset used for
TSP analysis consisted of 13 GP3 and 18 GP4 samples
(Additional file 7: Figure S3).
TSP analysis identified a top-scoring pairATG5/GLUT1
with a score of 0.547, capable of correctly classifying
24/31 (77.4%) samples. To be specific, with the order-
ing (Exp(ATG5) > Exp(GLUT1)), the scatterplot of Fig. 5
was generated. Permutation testing using 100,000 random
assignment classifications of GP3 and GP4 into groups
of 13 and 18 generated a distribution of scores (Fig. 6).
The low frequency of scores greater than 0.5 indicate that
a score of 0.547 for gene pair ATG5/GLUT1 is highly
significant (p = 0.0039).
Discussion
The roles of the stromal microenvironment and the RWE
have become increasingly noteworthy in the context of
cancer progression, and, as such, suggest a potential util-
ity of RWE-associated genes as prognostic biomarkers.
Our study has identified an RWE-associated gene, FOXO1
(AUC: 0.884), that is significantly differentially expressed
between GP3 and GP4 stroma, even after FDR correction,
as well as a multivariate top-scoring RWE-associated gene
pair, ATG5/GLUT1, whose relative expression can classify
GP in 77.4% of cases. The remaining eight genes, which
were significantly differentially expressed in both Welch
and MWU tests, but did not reach statistical significance
upon FDR correction, are also suggestive of additional
classifiers.
If reproducible in subsequent independent cohorts,
these RWE-associated biomarkers may have clinical value
in risk stratification. The identification of FOXO1 and
ATG5/GLUT1 in purified stroma and their differential
expression in aggressive vs. indolent prostate cancer sam-
ples indicate that it is possible to clinically categorize PCa
in terms of the metabolic responses, namely RWE, that
it elicits in the stroma. Additionally, if these gene expres-
sion changes extend appreciably beyond the immediate
tumor-stroma border, direct sampling of GP4 or GP3 may
become less necessary. For example, decreased expression
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Fig. 3 Boxplot of GP3 vs. GP4 expression for various genes. Notched boxplots for the eight genes, after FOXO1, which were found to be differentially
expressed. For these genes, the p value found in both a parametric (Welch t test) and non-parametric (Mann-Whitney U test) were less than 0.05,
indicating that both the means and medians differentiated between GP3 and GP4. The symbols and notation used in these plots are the same as
that employed in Fig. 1
of ATG5 relative to GLUT1 in a biopsy core showing
predominantly stroma or only low-grade cancer may indi-
cate the presence of nearby higher-grade cancer that was
missed by the biopsy. Evidence to suggest that this type of
“field effect” exists within the stroma includes studies that
show high autophagic turnover in fibroblasts at a distance
of up to 5mm away from the cancer [55].
In addition to the identification of two significant clas-
sifiers, this study has also provided potential insights into
the RWE response as it pertains to different grades of
PCa. The expression profiles of low-grade cancer stroma
reported here are consistent with Pavlides’ model of
the RWE, which depend on ROS-induced and HIF1A-
mediated transcription of genes encoding key glycolytic
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Table 2 Enrichment for GO biological processes using STRING
Term Number p q
of genes
Gluconeogenesis 4 5.92 × 10−8 4.54 × 10−4
Hexose catabolic process 4 1.42 × 10−7 4.54 × 10−4
Monosaccharide catabolic process 4 2.33 × 10−7 4.86 × 10−4
enzymes, transporters, and autophagic vesicle assembly
factors [35]. The upregulation of MCT4 seen here is
consistent with the induction of reciprocal lactate shut-
tling during RWE [56]. Similarly, the upregulation of
genes, HK2, ALDOA, GPD2, and ATG5, which are pre-
requisites for responses to high glycolytic influx and
auto-phagosome formation, respectively, are also con-
sistent with the literature on RWE induction [25, 57].
Interestingly, both of the statistically meaningful classi-
fiers, FOXO1 and ATG5, are directly implicated in the
activation of themitochondrial autophagy response.More
specifically, FOXO1 promotes the transcription of the
ATG5 gene [58]. These congruent results, achieved via
two different means of data processing, highlight an asso-
ciation between autophagy and GP3 and validate earlier
studies that identify mitochondrial dysfunction as the pri-
mary mechanism of RWE induction in CAFs [40, 55].
Similarly, sinceGLUT1 expression in stromal cells reflects
their ability to import and metabolize glucose, the relative
expression of the TSP genesATG5>GLUT1may indicate
that autophagy may be more important to RWE estab-
lishment and maintenance than upregulation of glucose
intake.
It is, however, noteworthy that other common
mitophagy markers such as BNIP3 and MAP1LC3B were
not found to be differentially expressed between the
Gleason patterns. ATG5 and BNIP3 participate in early
and late autophagy response, respectively [59], and there-
fore the upregulation of ATG5 primarily points towards a
role for early autophagosome formation in GP3-induced
RWE. HIF1A also showed no significant difference in
expression; however, upon enrichment for GO biological
Fig. 4 Protein-protein interactions network generated using STRING. The network is made up of the 17 upregulated genes in GP3 relative to GP4
(FOXO1, GPD2, HK2, MYC, ALDOA, SLC16A4, ATG5, TGFB2, TGFB3, EGLN1, GAPDH, CA9, P4HA1, MXI1, MMP9, and PGM1), plus five enriched genes
(ATG16L1, ATG12, AKT1, SIRT1, and SIRT3). The network centers on the primary nodal points: FOXO1, AKT1, MYC, and HIF1A, which show the largest
number of reciprocal inhibitory and activating functions with each other as well as with their interacting proteins. Activation (green), inhibition (red),
binding (blue), post-translational modification (fuchsia), reaction (black line). Directionality is indicated by the arrow
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Fig. 5 TSP scatterplot. Scatterplot illustrating the separation of GP3 and GP4 using the expression intensities of gene pair ATG5/GLUT1. With the
ordering Exp(ATG5) > Exp(GLUT1), 24/31 (77.4%) samples were correctly classified. One outlier (which agrees with the ordering) has been left out
for clarity
Fig. 6 TSP random classification distribution. Distribution of 100,000 random classification assignment TSP samplings. The low frequency of high
scores indicates that the score (0.547—red line) identified for top-scoring gene pair (ATG5/GLUT1) is unlikely to be due to chance (p = 0.0039)
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processes, responses to hypoxia and oxygen availability
were revealed to be significant. Lastly, we did not observe
expression differences in LDHA and LDHB, the enzymes
involved in conversion of pyruvate to lactate, or in PDK1
which regulates the flux into the tricarboxylic acid cycle.
In our context, this may indicate that lactate production
may not be as important as lactate export to the RWE in
PCa.
Relative to stroma from low-grade cancer, higher-grade
stroma exhibited gene expression patterns that indi-
cated a reduced RWE response. These results are in
agreement with studies conducted by Koukourakis et al.
[60–62] and Rattigan et al. [63] who have reported that
CAFs isolated from both lung and colorectal cancers
retain their oxidative phosphorylation potential, likely
in order to recycle the high volume of lactate secreted
by more aggressive tumors. These results also corrob-
orate studies conducted on breast and pancreatic can-
cers that have reported the reduced importance of RWE
in more aggressive disease subtypes such as TNBC
and HER2+ [64]. This reduction in RWE response in
GP4 relative to GP3 foci leads us to speculate that
RWE is perhaps a characteristic of a predominantly
proliferative phenotype with rather than invasion and
metastasis.
This switch from a predominantly proliferative phe-
notype in low-grade cancer to an invasive phenotype
in higher-grades may explain why genes (COL1A2 and
SPARC) coding for extracellular matrix (ECM) proteins
are independently upregulated in higher-grade stroma but
not in low-grade stroma. Cross-linking of CAF-secreted
collagens has been shown to promote tumor invasion
by increasing ECM stiffness [65]. Binding of secreted
COL1A2 to integrins, such as integrin α2β1 on the surface
of tumors, has also been shown to drive tumor cell migra-
tion via the activation of RhoC and PI3 kinase [66]. SPARC
has been shown to promote type 1 collagen fibril accumu-
lation and remodelling and to facilitate migration of CAFs
by decreasing adhesion to the ECM [67]. Interestingly,
SPARC may also play an additional role in controlling
metabolism. Its overexpression in the epithelial compart-
ment has been shown to decrease glucose uptake and
lactate production [68].
Finally, based on the protein-protein network analysis
presented here, we propose that the reduction in RWE
that we have observed occurs through the mediation
of FOXO1 function. FOXO1 is controlled by competing
pathways in the cell, namely activation by ROS [69–71],
and inhibition via the insulin-activated PI3K/AKT path-
way [72]. Decreased expression of ATG5 in high-grade
stroma is consistent with the effects of an activated
PI3K/AKT1 pathway. The tendency of GP4 foci to over-
express growth signals such as IGF and EGFR may serve
to explain FOXO1 activation in response to GP3 but
not GP4 [73]. These results further illustrate the rela-
tionship between PCa phenotype and stromal metabolic
response.
Conclusions
Few studies have investigated the use of RWE-associated
genes in a prognostic setting. In this study, we have iden-
tified two potential classifiers, stromal FOXO1 and stro-
mal ATG5/GLUT1, which have the potential to be used
to distinguish between aggressive and indolent forms of
PCa. Future directions should include validation of either
FOXO1 expression or ATG5/GLUT1 relative expression
classifiers in a larger cohort of independent tissue sam-
ples. Additionally, we report reduced expression of an
RWE gene signature in high-grade stroma, a finding suf-
ficiently robust to achieve significance under two inde-
pendent statistical analyses. Based on the pathway anal-
ysis presented here, this reduction is likely mediated by
FOXO1 and AKT1 signalling. Since the role that the RWE
and its associated functional pathways play in PCa growth
has to our knowledge not been previously explored, the
work reported here indicates the potential benefits of
investigating, measuring, and manipulating this pathway
in PCa.
Additional files
Additional file 1: Clinical data. Table S1. Correlations between GP3 and
GP4 and secondary clinical characteristics: age, pre-op PSA, % cancer tissue
volume, and pathological stage. (PDF 43.5 kb)
Additional file 2: Gene/accession numbers. Table S2. RWE code-set
accession numbers. (XLSX 46.8 kb)
Additional file 3: MTE primer sequences. Table S3.MTE primer
sequences. (XLSX 45.9 kb)
Additional file 4: NanoString probe sequences. Table S4.
NanoSNanoStringtring probe sequences. (XLSX 42.1 kb)
Additional file 5: NanoString positive controls. Figure S1. Plot of the log2
raw expression values for six positive controls ranging from a
concentration of 128 to 0.128 fM. Each box-whisker construct represents
one positive control. The settings for the notched box-whisker plots are the
same as those in the main text (see caption to Fig. 1). (PDF 5.09 kb)
Additional file 6: NanoString negative controls. Figure S2. Plot of the
log2 raw expression values for eight negative controls. The broad
distribution is likely due to the fragmentation of small input samples. The
broad distribution of the negative controls indicates that the low intensity
data is going to be less reliable. Each box-whisker construct represents one
negative control. The settings for the notched box-whisker plots are the
same as those in the main text (see caption to Fig. 1). (PDF 5.52 kb)
Additional file 7: NanoString housekeeping genes. Figure S3. Plot of the
log2 raw expression values for the five selected housekeeping genes.
Distribution of expression values is very broad within each gene; HPRT1
and TUBB have particularly long whisker ranges of 5000. The very broad
distribution of these housekeeping genes in stromal tissue made them
unamendable to the calculation of normalization factors; therefore
normalization factors were calculated using the geometric mean of the top
75 genes within a sample. The settings for the notched box-whisker plots
are the same as those in the main text (see caption to Fig. 1). (PDF 5.02 kb)
Georgescu et al. Cancer &Metabolism  (2016) 4:8 Page 11 of 12
Abbreviations
AUC: area under the curve; CAF: cancer-associated fibroblast; ECM:
extracellular matrix; FDR: false discovery rate; FFPE: formalim-fixed
paraffin-embedded; FOV: field of view; GO: Gene Ontology; GP: Gleason
pattern; GS: Gleason score; MTE: multiplex target enrichment; MWU:
Mann-Whitney U; PCa: prostate cancer; ROC: receiver operator characteristics;
ROS: reactive oxygen species; TSP: top-scoring pair.
Competing interests
DMB serves as a paid consultant and has a financial interest in Metamark
Genetics. All other authors declare that they have no competing interests.
Authors’ contributions
DB and PCP completed the pathology reviews of the prostate tissues. CD
performed the chart reviews and provided the patient data examined by AD.
RJG helped develop a normalization script, as well as with the univariate
statistical analysis of the nCounter expression data. RJG also performed the
TSP analysis. IG performed all experiments outlined in this study. Experimental
and study design were completed by PCP and IG. As primary author, IG wrote
the manuscript, with inputs from RJG, SS, DMB, and PCP. No other co-authors
to declare. All authors read and approved the final manuscript.
Acknowledgements
This study was supported by research grants from the Prostate Cancer Fight
Foundation and by Prostate Cancer Canada, Grant #T2014-01, and proudly
funded by the Movember Foundation. PCP was supported by the Ontario
Institute for Cancer Research Transformative Pathology Fellowship Program. IG
was supported by the Terry Fox Foundation Training Program in
Transdisciplinary Cancer Research in partnership with the Canadian Institute of
Health Research.
Author details
1Department of Pathology and Molecular Medicine, Queen’s University,
Kingston, ON, Canada. 2Division of Cancer Biology and Genetics, Cancer
Research Institute, Queen’s University, Kingston, ON, Canada. 3Department of
Physics, Engineering Physics and Astronomy, Queen’s University, Kingston, ON,
Canada. 4Department of Urology, Queen’s University, Kingston, ON, Canada.
5NCIC Clinical Trials Group, Queen’s University, Kingston, ON, Canada. 6Ontario
Institute for Cancer Research, Toronto, ON, Canada.
Received: 5 December 2015 Accepted: 29 March 2016
References
1. Gleason D, Mellinger G. Prediction of prognosis for prostatic
adenocarcinoma by combined histological grading and clinical staging.
J Urol. 1974;111:58–64.
2. Stark J, Perner S, Mucci L. Gleason score and lethal prostate cancer: does
3 + 4 = 4 + 3? J Clin Oncol. 2009;27(21):3459–64.
3. Fine S, Epstein J. A contemporary study correlating prostate needle
biopsy and radical prostatectomy Gleason score. J Clin Oncol.
2009;179(4):1335–39.
4. Beltran H, Rubin M. New strategies in prostate cancer: translating
genomics into clinic. Clin Cancer Res. 2013;19(3):517–22.
5. Berger M, Lawrence M, Demichelis F, Drier Y, Cibulskis K, Sivachenko A,
et al. The genomic complexity of primary human prostate cancer. Nat.
2011;470:214–0.
6. Barbieri C, Baca S, Lawrence M, Demichelis F, Blattner M, Theurillat J,
et al. Exome sequencing identifies recurrent SPOP, FOXA1 andMED12
mutations in prostate cancer. Nat Genet. 2012;44:685–9.
7. Grasso C, Wu Y, Robinson D, Cao X, Dhanasekaran S, Khan A, et al. The
mutational landscape of lethal castration-resistant prostate cancer. Nat.
2012;487:239–43.
8. Taylor B, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver B, et al.
Integrative genomic profiling of human prostate cancer. Cancer Cell.
2010;18:11–22.
9. Cuzick J, Swanson G, Fisher G, Brothman A, Berney D, et al. Prognostic
value of an RNA expression signature derived from cell cycle proliferation
genes in patients with prostate cancer: a retrospective study. Lancet
Oncol. 2011;12:245–55.
10. Blume-Jensen P, Berman D, Rimm D, Shipitsin M, Putzi M, et al.
Development and clinical validation of an in situ biopsy-based
multimarker assay for risk stratification in prostate cancer. Clin Canc Res.
2011;21(11):2591–600.
11. Erho N, Crisan A, Vergara I, Mitra A, Ghadessi M, et al. Discovery and
validation of a prostate cancer genomic classifier that predicts early
metastasis following radical prostatectomy. PLOS One. 2013;8(6):
66855.
12. Klein E, Cooperberg M, Magi-Galluzzi C, Simko J, Falzarano S, Maddala T,
et al. A 17-gene assay to predict prostate cancer aggressiveness in the
context of Gleason grade, heterogeneity, tumour multifocality, and
biopsy undersampling. Eur Urol. 2014;66(3):550–60.
13. True L, Coleman I, Hawley S, Huang C, Gifford D, Coleman R, et al. A
molecular correlate to the Gleason grading system for prostate
adenocarcinoma. PNAS. 2006;103(29):10991–6.
14. Irshad S, Bansal M, Castillo-Martin M, Zheng T, Aytes A, Wenske S, et al.
A molecular signature predictive of indolent prostate cancer. Sci Transl
Med. 2013;5(202):202–122.
15. Lapointe J, Li C, Higgins J, van de Rijn M, Bair E, Montgomery K, et al.
Gene expression profiling identifies clinically relevant subtypes of
prostate cancer. PNAS. 2004;101:811–16.
16. Chung L, Baseman A, Assikis V, Zhau H. Molecular insights into prostate
cancer progression: the missing link of tumor microenvironment. J Urol.
2005;173(1):10–20.
17. Kaminski A, Hahne J, Haddouti e-M, Florin A, Wellmann A, Wernert N.
Tumour-stroma interactions between metastatic prostate cancer cells
and fibroblasts. Int J Mol Med. 2006;18(5):941–50.
18. Mueller M, Fusenig N. Friends or foes—bipolar effects of the tumour
stroma in cancer. Nat Rev Cancer. 2004;4(11):839–49.
19. Wiseman B, Werb Z. Stromal effects on mammary gland development
and breast cancer. Science. 2002;296(5570):1046–49.
20. Olumi A, Grossfeld G, Hayward S, Carroll P, Tisty T, Cunha GR.
Carcinoma-associated fibroblasts direct tumor progression of initiated
human prostatic epithelium. Cancer Res. 1999;59(19):5002–11.
21. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T,
Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts
present in invasive human breast carcinomas promote tumor growth and
angiogenesis through elevated SDF-1/CXCL12 secretion. Cell.
2005;121(3):335–48.
22. DeWever O, Mareel M. Role of tissue stroma in cancer cell invasion.
J Pathol. 2004;200(4):429–7.
23. Desmouliere A, Guyot C, Gabbiani G. The stroma reaction myofibroblast:
a key player in the control of tumor cell behavior. Int J Dev Biol.
2004;48(5–6):509–17.
24. Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L. Reciprocal
activation of prostate cancer cells and cancer-associated fibroblasts
stimulates epithelial-mesenchymal transition and cancer stemness.
Cancer Res. 2010;70(17):6945–56.
25. Martinez-Outschoorn U, Pavlides S, Howell A, Pestell R, Tanowitz H,
Sotgia F, et al. Stromal-epithelial metabolic coupling in cancer:
integrating autophagy and metabolism in the tumor microenvironment.
Int J Biochem Cell Biol. 2011;43(7):1045–51.
26. Sonveaux P, Vegran F, Schroeder T, Wergin M, Verrax J, Rabbani Z, et al.
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in
mice. J Clin Invest. 2008;118(12):3930–42.
27. Martinez-Outschoorn U, Balliet R, Rivadeneira D, Chiavarina B, Pavlides
S, Wang C, et al. Oxidative stress in cancer associated fibroblasts drives
tumor-stroma co-evolution: a new paradigm for understanding tumor
metabolism, the field effect and genomic instability in cancer cells. Cell
Cycle. 2010;9:3256–76.
28. Martinez-Outschoorn U, Trimmer C, Lin Z, Whitaker-Menezes D,
Chiavarina B, Zhou J, et al. Autophagy in cancer associated fibroblasts
promotes tumor cell survival: role of hypoxia, HIF1 induction and NFκβ
activation in the tumor stromal microenvironment. Cell Cycle. 2010;9:
3515–3.
29. Ma X, Dahiya S, Richardson E, Erlander M, Sgroi D. Gene expression
profiling of the tumor microenvironment during breast cancer
progression. Breast Cancer Res. 2009;11(1):7.
30. Trujillo K, Jones A, Griffith J, Bisoffi M. Markers of field cancerization:
proposed clinical applications in prostate biopsies. Prostate Cancer.
2012;2012:302894.
Georgescu et al. Cancer &Metabolism  (2016) 4:8 Page 12 of 12
31. Walter K, Omura N, Hong S, Griffith M, Goggins M. Pancreatic cancer
associated fibroblasts display normal allelotypes. Cancer Biol Ther.
2008;7(6):882–8.
32. Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, et al. No evidence
of clonal somatic genetic alterations in cancer-associated fibroblasts from
human breast and ovarian carcinomas. Nat Genet. 2008;40(5):650–55.
33. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et
al. Molecular characterization of the tumor microenvironment in breast
cancer. Cancer Cell. 2004;6(1):17–32.
34. Campbell I, Polyak K, Haviv I. Clonal mutations in the cancer-associated
fibroblasts: the case against genetic coevolution. Cancer Res. 2009;69(17):
6765–9.
35. Mohler J, Bahnson R, Boston B, Busby J, D’Amico A, Eastham J, et al.
NCCN clinical practice guidelines in oncology: prostate cancer. J Natl
Compr Canc Netw. 2010;8(2):162–200.
36. Epstein J, Allsbrook WJ, Amin M, Egevad L. ISUP Grading Committee:
The 2005 International Society of Urological Pathology (ISUP) consensus
conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol.
2005;29:1228–42.
37. Vander Heiden M, Cantley L, Thompson C. Understanding the Warburg
effect: the metabolic requirements of cell proliferation. Science. 2009;324:
1029–33.
38. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N,
Witkiewicz A, Frank P, et al. The reverse Warburg effect: aerobic glycolysis
in cancer associated fibroblasts and the tumor stroma. Cell cycle. 2009;8:
3984–4001.
39. Gonzalez C, Alvarez S, Ropolo A, Rosenzvit C, Bagnes M, Vaccaro M.
Autophagy, Warburg, and Warburg reverse effects in human cancer.
Biomed Res Int. 2014;2014:926729.
40. Pavlides S, Tsirigos A, Vera I, Flomenberg N, Frank P, Casimiro M, et al.
Transcriptional evidence for the “reverse Warburg effect” in human breast
cancer tumor stroma and metastasis: similarities with oxidative stress,
inflammation, Alzheimer’s disease and “Neuron-Glia Metabolic Coupling”.
Aging. 2010;2:185–99.
41. Witkiewicz A, Kline J, Queenan M, Brody J, Tsirigos A, Bilal E, et al.
Molecular profiling of a lethal tumor microenvironment, as defined by
stromal caveolin-1 status in breast cancers. Cell Cycle. 2011;10:1794–809.
42. Sotgia F, Del Galdo F, Casimiro M, Bonuccelli G, Mercier I,
Whitaker-Menezes D, et al. Caveolin-1-/- null mammary stromal
fibroblasts share characteristics with human breast cancer-associated
fibroblasts. Am J Pathol. 2009;174:746–61.
43. Edgar R, Domrachev M, Lash A. Gene Expression Omnibus: NCBI gene
expression and hybridization array data repository. Nucleic Acids Res.
2002;30(1):207–10.
44. Ashida S, Orloff M, Bebek G, Zhang L, Zheng P, Peehl D, et al. Integrated
analysis reveals critical genomic regions in prostate tumor
microenvironment associated with clinicopathologic phenotypes. Clin
Cancer Res. 2012;18(6):1578–87.
45. Planche A, Bacac M, Provero P, Fusco C, Delorenzi M, Stehle J, et al.
Identification of prognostic molecular features in the reactive stroma of
human breast and prostate cancer. PLoS One. 2011;6(5):18640.
46. Dakhova O, Ozen M, Creighton C, Li R, Ayala G, Rowley D, et al. Global
gene expression analysis of reactive stroma in prostate cancer. Clin
Cancer Res. 2009;15(12):3979–89.
47. Ohl F, Jung M, Xu C, Stephan C, Rabien A, Burkhardt M, et al. Gene
expression studies in prostate cancer tissue: which reference gene should
be selected for normalization. J Mol Med. 2005;83:1014–24.
48. Waggott D, Chu K, Yin S, Wouters B, Liu F, Boutros P. NanoStringNorm:
an extensible R package for the pre-processing of NanoString mRNA and
miRNA data. Bioinformatics. 2012;28:1546–48.
49. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J R Statist Soc B. 1995;57(1):
289–300.
50. Geman D, D’avignon C, Naiman D, Winslow R. Classifying gene
expression profiles from pairwise mRNA comparisons. Stat Appl Genet
Mol Biol. 2004;3:1–19.
51. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, et al. STRING
v10: protein-protein interaction networks, integrated over the tree of life.
Nucleic Acids Res. 2015;43(Database issue):447–52.
52. Warde-Farley D, Donaldson S, Comes O, Zuberi K, Badrawi R, Chao P,
et al. The GeneMANIA prediction server: biological network integration
for gene prioritization and predicting gene function. Nucleic Acids Res.
2010;1(38 Suppl):214–0.
53. The Gene Ontology. The Gene Ontology Consortium: going forward.
Nucleic Acids Res. 2015;43(Database issue):1049–1056.
54. Newell J, Patrick S, Clawson G. RNA quality analysis of tumor bank
specimens and downstream applicability. FASEB J. 2012;26:1034–15.
55. Chaudhri V, Salzler G, Dick S, Buckman M, Sordella R, Karoly E, et al.
Metabolic alterations in lung cancer-associated fibroblasts correlated
with increased glycolytic metabolism of the tumor. Mol Cancer Res.
2013;11(6):579–92.
56. Fiaschi T, Marini A, Giannoni E, Taddei M, Gandellini P, De Donatis A,
et al. Reciprocal metabolic reprogramming through lactate shuttle
coordinately influences tumor-stroma interplay. Cancer Res. 2012;72:
5130–40.
57. Zhao X, He Y, Chen H. Autophagic tumor stroma: mechanisms and roles
in tumor growth and progression. Int J Cancer. 2013;132:1–8.
58. Xu P, Das M, Reilly J, David R. JNK regulates FoxO-dependent autophagy
in neurons. Genes & Dev. 2011;25:310–22.
59. Mehrpour M, Esclatine A, Beau I, Codogno P. Overview of
macroautophagy regulation in mammalian cells. Cell Res. 2010;20:748–62.
60. Koukourakis M, Giatromanolaki A, Sivridis E, Gatter K, Harris A. Pyruvate
dehydrogenase and pyruvate dehydrogenase kinase expression in non
small cell lung cancer and tumor-associated stroma. Neoplasia.
2005;7(1):1–6.
61. Koukourakis M, Giatromanolaki A, Harris A, Sivridis E. Comparison of
metabolic pathways between cancer cells and stromal cells in colorectal
carcinomas: a metabolic survival role for tumor-associated stroma. Cancer
Res. 2006;66:632–37.
62. Koukourakis M, Giatromanolaki A, Bougioukas G, Sivridis E. Comparison
of metabolic pathways between cancer cells and stromal cells in
colorectal carcinomas: a metabolic survival role for tumor-associated
stroma. Cancer Biol Ther. 2007;6(9):1476–79.
63. Rattigan Y, Patel B, Ackerstaff E, Sukenick G, Koutcher J, Glod J, et al.
Lactate is a mediator of metabolic cooperation between stromal
carcinoma associated fibroblasts and glycolytic tumor cells in the tumor
microenvironment. Exp Cell Res. 2012;318:326–5.
64. Choi J, Kim dH, Jung W, Koo J. Metabolic interaction between cancer
cells and stromal cells according to breast cancer molecular subtype.
Breast Cancer Res. 2012;15(5):78.
65. Karagiannis G, Poutahidis T, Erdman S, Kirsch R, Riddell R, Diamandis E.
Cancer-associated fibroblasts drive the progression of metastasis through
both paracrine and mechanical pressure on cancer tissue. Mol Cancer
Res. 2012;10:1403–18.
66. Kirkland S. Type I collagen inhibits differentiation and promotes a stem
cell-like phenotype in human colorectal carcinoma cells. Br J Cancer.
2009;101(2):320–6.
67. Strandjord T, Madtes D, Weiss D, Sage H. Collagen accumulation is
decreased in SPARC-null mice with bleomycin-induced pulmonary
fibrosis. AJP-Lung. 1999;277(3):628–35.
68. Hua H, Jiang F, Huang Q, Liao Z, Ding G. Re-sensitization of 5- FU
resistance by SPARC through negative regulation of glucose metabolism
in hepatocellular carcinoma. Tumour Biol. 2015;26(1):303–13.
69. Nakae J, Kitamura T, Silver D, Accili D. The forkhead transcription factor
Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase
expression. J Clin Invest. 2001;108(9):1359–67.
70. Chen C, Jeon S, Bhaskar V, Nogueira V, Sundararajan D, Tonic I, et al.
FoxOs inhibit mTORC1 and activate Akt by inducing the expression of
Sestrin3 and R. Dev Cell. 2010;18(4):592–604.
71. Webb A, Brunet A. FoxO transcription factors: key regulators of cellular
quality control. Trends Biochem Sci. 2014;39:159–69.
72. van der Horst A, Burgering B. Stressing the role of FoxO proteins in
lifespan and disease. Nat Rev Mol Cell Biol. 2007;8(6):440–50.
73. Skacel M, Ormsby A, Pettay J, Tsiftsakis E, Liou L, Klein E, et al.
Aneusomy of chromosones 7, 8, and 17 and amplification of HER-2/neu
and epidermal growth factor receptor in Gleason score 7 prostate
carcinoma: a differential fluorescent in situ hybridization study of Gleason
pattern 3 and 4 using tissue microarray. Hum Pathol. 2001;32(12):1392–7.
